HSBC/CALL/MODERNA/260/0.1/15.01.25 Stock

DE000HG807M9

Market Closed - Boerse Frankfurt Warrants 03:35:34 2024-05-24 pm EDT
0.86 ^EUR	+6.17%

Current month	+671.19%
1 month	+705.31%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Chart HSBC/CALL/MODERNA/260/0.1/15.01.25

Latest news about MODERNA, INC.

Novavax awaits FDA decision on whether its next COVID shot can be offered in US	May. 24	RE
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	May. 23
Moderna Announces Data to be presented at 2024 ASCO Annual Meeting	May. 23	AQ
The market is good to go until Nvidia’s next quarterly results	May. 23

More news

Quotes 5-day view

Date	Price	Change
24-05-24	0.91	+12.35%
24-05-23	0.81	+2.53%
24-05-22	0.79	+139.39%
24-05-21	0.33	+13.79%
24-05-20	0.29	+45.00%

Real-time Boerse Frankfurt Warrants

Last update May 24, 2024 at 03:35 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	HSBC
WKN	HG807M
ISIN	DE000HG807M9
Date issued	2023-02-02
Strike	260 $
Maturity	2025-01-15 (236 Days)
Parity	10 : 1
Emission price	3.27 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	3.17 €
Lowest since issue	0.044 €
Spread	0.02 €
Spread %	2.27%

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company